Search Results - "Catarig, A M"

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) by Capehorn, M.S., Catarig, A.-M., Furberg, J.K., Janez, A., Price, H.C., Tadayon, S., Vergès, B., Marre, M.

Get full text

Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT) by Knudsen, S. T., Lapolla, A., Schultes, B., Tentolouris, N., Catarig, A.‐M., Wolden, M. L., Siegmund, T.

“…Aims To investigate whether the benefits of switching to insulin degludec observed in the European retrospective chart review study EU‐TREAT were dependent on…”
Get full text

Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) by Capehorn, M.S., Catarig, A.-M., Furberg, J.K., Janez, A., Price, H.C., Tadayon, S., Vergès, B., Marre, M.

“…SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent semaglutide dose (1.0mg) with the current most frequently prescribed liraglutide…”
Get full text

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study by Rajamand Ekberg, Neda, Bodholdt, Ulrik, Catarig, Andrei-Mircea, Catrina, Sergiu-Bogdan, Grau, Katrine, Holmberg, Cecilia Nagorny, Klanger, Boris, Knudsen, Søren Tang

“…[Display omitted] •Real-world SURE programme data complement those from the SUSTAIN clinical trials.•SURE Denmark/Sweden studied local use of once-weekly…”
Get full text

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups by Yale, Jean-François, Bodholdt, Ulrik, Catarig, Andrei-Mircea, Catrina, Sergiu, Clark, Alice, Ekberg, Neda Rajamand, Erhan, Umut, Holmes, Patrick, Knudsen, Søren Tang, Liutkus, Joanne, Sathyapalan, Thozhukat, Schultes, Bernd, Rudofsky, Gottfried

“…IntroductionThis post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of…”
Get full text

Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study by Lassen, M C H, Johansen, N D, Modin, D, Catarig, A M, Vistisen, B K, Amadid, H, Zimmermann, E, Gislason, G, Biering-Soerensen, T

“…Abstract Background The use of glucagon-like peptide-1 receptor agonsists (GLP-1 RA) continues to rise and is increasingly important in the treatment of type-2…”
Get full text

Patients reaching treatment targets with once-weekly semaglutide in real-world practice: pooled analysis of four SURE studies by Rudofsky, G, Bodholdt, U, Catarig, AM, Ekberg, NR, Erhan, U, Liutkus, JF, Tariq, M, Holmes, P

Get full text

Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies by Yale, JF, Catarig, AM, Catrina, SB, Erhan, U, Sathyapalan, T, Schultes, B, Tariq, M, Knudsen, ST

Get full text